ArticleJournal of cardiology cases2019
Efficacy and safety of apixaban in a patient with systemic venous thromboembolism associated with hereditary antithrombin deficiency.
Article in Journal of cardiology cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Severe Hemoperitoneum From a Ruptured Ovarian Cyst in a Patient with Antiphospholipid Syndrome and Antithrombin III Deficiency: A Case Report.The American journal of case reports · 2025Article
- Secondary prophylaxis of venous thromboembolism (VTE) with low dose apixaban or rivaroxaban in major-thrombophilia carriers.Annals of hematology · 2024Article
- Article
- Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.International journal of molecular sciences · 2022Review
- Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study.International journal of hematology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 40-year-old man with progressively worsening dyspnea was admitted to our hospital. On physical examination, pulse oximetry results demonstrated 80% oxygen saturation in room air. The lungs sounded clear, and both extremities appeared normal, without pitting edema. His echocardiography revealed a pressure overload in the right ventricle. Suspecting the presence of pulmonary thromboembolism, we performed an enhanced computed tomography (CT). CT results revealed systemic venous thromboembolism (VTE) involving the superior mesenteric vein, inferior vena cava (IVC), right common iliac vein and pulmonary arteries, as well as splenomegaly and edema of the small intestine with ascites. After insertion of a retrievable IVC filter, we prescribed 10 mg of apixaban twice daily for the first 7 days, followed by 5 mg twice daily as long-term therapy. Confirming no exacerbation of the VTE symptoms, we removed the IVC filter 14 days after admission. Additionally, hereditary antithrombin deficiency was unraveled as the etiology of systemic VTE. Although an enhanced CT at 6 months follow-up showed that almost all previous VTE had dissolved, we decided to prescribe apixaban indefinitely. Fortunately, he has not experienced a recurrence of VTE or any bleeding events to date. <
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.